Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — J.P. Morgan 41st Annual Healthcare Conference 2023
25 slides from Summit Therapeutics's conference presentation, Jan 9, 2023
Slide 1: J.P. Morgan 41st Annual Healthcare Conference 2023
J.P. Morgan 41st Annual Healthcare Conference 2023 Bob Duggan Dr. Maky Zanganeh Chairman & CEO Co-CEO, President & Board Member
Slide 2: Disclaimer and Forward-Looking Statement
2 Disclaimer and Forward-Looking Statement Any statements in this presentation about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to
Slide 3: Summit Therapeutics, Inc. Overview
Summit Therapeutics, Inc. Overview NASDAQ LISTED COMPANY SMMT Menlo Park, CA Oxford & Cambridge, UK OFFICES 2020 Became a US Entity Listed on NASDAQ Assembled a World-Class Team 2021 Signed Licensing Agreement Between Summit and Akeso for Ivonescimab (Novel Bispecific Antibody for Development in Onc
Slide 4: Building a Company with IMPACT
WHERE WE ARE GOING Building a Company with IMPACT Focused on novel innovations ꟷ Developing ivonescimab across multiple oncology indications ꟷ In-house discovery and research on oncology molecules WHO WE ARE Leadership with Game-Changing Experience Leaders with global oncology experience Proven trac
Slide 5: Partnership with Akeso
Partnership with q Akeso
Slide 6: Strategic Partnership with an Aligned Mission
Strategic Partnership with an Aligned Mission Bringing Ivonescimab to Patients in Need Summit Therapeutics SMT112 United States, Canada, Europe & Japan (Summit License Territories) Akeso AK112 China & Non-Summit Territories 6 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprie
Slide 7: Akeso: A Pioneer in Developing Innovative Antibodies
Akeso: A Pioneer in Developing Innovative Antibodies 7 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Focus on innovative therapeutic antibodies Founded in 2012 Headquartered in Zhongshan (near Hong Kong) China Liste
Slide 8: Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody Overview
Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody Overview
Slide 9: Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody
Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody Anti-VEGF Anti-PD-1 Ivonescimab is a novel potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking of VEGF into a single molecule 9 J.P. M
Slide 10: Simultaneous blockage of PD-1 & VEGF enhances anti-tumor activity
SMT112 Simultaneous blockage of PD-1 & VEGF provides enhanced anti- tumor activities Tighter binding and higher specificity enhances T cell activation Tumor Microenvironment Without PD-1 or VEGF Antibodies With Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody 2. VEGF induces angiogenesis which giv
Slide 11: Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody
• The most advanced PD-1/VEGF bispecific antibody in clinical development • Received breakthrough therapy designation status in China for three indications1 • Combined with chemotherapy for NSCLC patients who have failed a previous EGFR-TKI • Combined with chemotherapy for NSCLC patients who have fa
Slide 12: Ivonescimab Clinical Overview
Ivonescimab Clinical Overview
Slide 13: Phase Ib/II Monotherapy NSCLC Study Design
13 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical studies. Zhao Y,
Slide 14: Study Results: Ivonescimab Monotherapy
Study Results 14 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical stu
Slide 15: Phase II Ivonescimab + Chemo NSCLC Study Design
15 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical studies. Zhao Y,
Slide 16: Study Results: Combination Therapy, First-Line NSCLC
Study Results 16 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical stu
Slide 17: Study Results: Combination Therapy, Post EGFR-TKI
Study Results 17 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical stu
Slide 18: Study Results: Combination Therapy, Post PD-(L)1
Study Results 18 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical stu
Slide 19: Phase II Safety Results with Chemotherapy
19 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Ivonescimab is an investigational therapy that is not approved by any regulatory authority: It is currently being investigated in Phase III clinical studies. • Ivones
Slide 20: Lead Indications: NSCLC
Lead Indications: NSCLC Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody
Slide 21: Lung Cancer
1. Lung Cancer Fact Sheet | American Lung Association 2. Lung Cancer Facts: 29 Statistics and Facts | LCFA (lcfamerica.org) 3. What Is Lung Cancer? | Types of Lung Cancer Lung Cancer Leading cause of death in cancer patients in the U.S.1 Every 4 minutes someone in the U.S. dies of lung cancer 2 236,
Slide 22: Summit Therapeutics Oncology Pipeline
Summit Therapeutics Oncology Pipeline 22 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Subject to Hart-Scott-Rodino (HSR) Act Ivonescimab is an investigational therapy that is not approved by any regulatory authorit
Slide 23: Licensing Agreement with Akeso & Financial Details
Licensing Agreement with Akeso & Financial Details
Slide 24: In-Licensing and Financial Update
In-Licensing and Financial Update 24 J.P. Morgan 41st Annual Healthcare Conference, January 2023 Summit Proprietary Information - Do Not Copy, Photograph or Distribute Subject to Hart-Scott-Rodino (HSR) Act • Upfront payment: $500 million ꟷ $25 million to be paid via 10 million shares; the remainder
Slide 25: Q&A
J.P. Morgan 41st Annual Healthcare Conference 2023 Q&A Bob Duggan Dr. Maky Zanganeh Chairman & CEO Co-CEO, President & Board Member
Summit Therapeutics — J.P. Morgan 41st Annual Healthcare Conference 2023 on 6ix